Simvastatin for patients with acute respiratory distress syndrome: long-term outcomes and cost-effectiveness from a randomised controlled trial.

Ashley AgusC HulmeR M VerghisC McDowellC JacksonC M O'KaneJ G LaffeyD F McAuley

Published in: Critical care (London, England) (2017)

Simvastatin was found to be cost-effective for the treatment of ARDS, being associated with both a significant QALY gain and a cost saving. There was no significant reduction in mortality at 12 months, TRIAL REGISTRATION: ISRCTN, 88244364. Registered 26 November 2010.

Keyphrases

acute respiratory distress syndrome
extracorporeal membrane oxygenation
mechanical ventilation
clinical trial
study protocol
cardiovascular events
phase iii
randomized controlled trial
phase ii
type diabetes
intensive care unit
open label
replacement therapy